Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12

1.

RGS9-2 rescues dopamine D2 receptor levels and signaling in DYT1 dystonia mouse models.

Bonsi P, Ponterio G, Vanni V, Tassone A, Sciamanna G, Migliarini S, Martella G, Meringolo M, Dehay B, Doudnikoff E, Zachariou V, Goodchild RE, Mercuri NB, D'Amelio M, Pasqualetti M, Bezard E, Pisani A.

EMBO Mol Med. 2019 Jan;11(1). pii: e9283. doi: 10.15252/emmm.201809283.

2.

Heroin versus cocaine: opposite choice as a function of context but not of drug history in the rat.

De Luca MT, Montanari C, Meringolo M, Contu L, Celentano M, Badiani A.

Psychopharmacology (Berl). 2018 Nov 15. doi: 10.1007/s00213-018-5115-1. [Epub ahead of print]

PMID:
30443795
3.

Dystonia: Are animal models relevant in therapeutics?

Meringolo M, Tassone A, Imbriani P, Ponterio G, Pisani A.

Rev Neurol (Paris). 2018 Nov;174(9):608-614. doi: 10.1016/j.neurol.2018.07.003. Epub 2018 Aug 25. Review.

PMID:
30153948
4.

Centrality of Early Synaptopathy in Parkinson's Disease.

Imbriani P, Schirinzi T, Meringolo M, Mercuri NB, Pisani A.

Front Neurol. 2018 Mar 1;9:103. doi: 10.3389/fneur.2018.00103. eCollection 2018. Review.

5.

Enhanced mu opioid receptor-dependent opioidergic modulation of striatal cholinergic transmission in DYT1 dystonia.

Ponterio G, Tassone A, Sciamanna G, Vanni V, Meringolo M, Santoro M, Mercuri NB, Bonsi P, Pisani A.

Mov Disord. 2018 Feb;33(2):310-320. doi: 10.1002/mds.27212. Epub 2017 Nov 18.

PMID:
29150865
6.

The neurobiological bases of autism spectrum disorders: the R451C-neuroligin 3 mutation hampers the expression of long-term synaptic depression in the dorsal striatum.

Martella G, Meringolo M, Trobiani L, De Jaco A, Pisani A, Bonsi P.

Eur J Neurosci. 2018 Mar;47(6):701-708. doi: 10.1111/ejn.13705. Epub 2017 Oct 4.

PMID:
28921757
7.

Evaluation of AZD1446 as a Therapeutic in DYT1 Dystonia.

Zimmerman CN, Eskow Jaunarajs KL, Meringolo M, Rizzo FR, Santoro M, Standaert DG, Pisani A.

Front Syst Neurosci. 2017 Jun 13;11:43. doi: 10.3389/fnsys.2017.00043. eCollection 2017.

8.

Intravenous self-administration of benzydamine, a non-steroidal anti-inflammatory drug with a central cannabinoidergic mechanism of action.

Avvisati R, Meringolo M, Stendardo E, Malavasi E, Marinelli S, Badiani A.

Addict Biol. 2018 Mar;23(2):610-619. doi: 10.1111/adb.12516. Epub 2017 Apr 21.

PMID:
28429885
9.

Differential vulnerability to relapse into heroin versus cocaine-seeking as a function of setting.

Montanari C, Stendardo E, De Luca MT, Meringolo M, Contu L, Badiani A.

Psychopharmacology (Berl). 2015 Jul;232(13):2415-24. doi: 10.1007/s00213-015-3877-2. Epub 2015 Feb 10.

PMID:
25662790
10.

Hyaluronic acid nanohydrogels as a useful tool for BSAO immobilization in the treatment of melanoma cancer cells.

Montanari E, Capece S, Di Meo C, Meringolo M, Coviello T, Agostinelli E, Matricardi P.

Macromol Biosci. 2013 Sep;13(9):1185-94. doi: 10.1002/mabi.201300114. Epub 2013 Jul 8.

PMID:
23836462
11.

The role of setting for ketamine abuse: clinical and preclinical evidence.

De Luca MT, Meringolo M, Spagnolo PA, Badiani A.

Rev Neurosci. 2012;23(5-6):769-80. doi: 10.1515/revneuro-2012-0078. Review.

PMID:
23159868
12.

Induction of morphine-6-glucuronide synthesis by heroin self-administration in the rat.

Meringolo M, Brusadin V, De Luca MT, Montanari C, Antonilli L, Nencini P, Badiani A.

Psychopharmacology (Berl). 2012 May;221(2):195-203. doi: 10.1007/s00213-011-2534-7. Epub 2011 Oct 21. Erratum in: Psychopharmacology (Berl). 2012 May;221(2):359. Montanari, Christian L [corrected to Montanari, Christian].

PMID:
22016196

Supplemental Content

Loading ...
Support Center